Literature DB >> 28488314

Pharmacist intervention to detect drug adverse events on admission to the emergency department: Two case reports of neuroleptic malignant syndrome.

F Leenhardt1, D Perier2, V Pinzani3, I Giraud2, M Villiet1, A Castet-Nicolas1, V Gourhant2, C Breuker1,4.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Neuroleptic malignant syndrome (NMS) is a rare but severe adverse effect of antipsychotic drugs. CASE DESCRIPTION: We report two cases of NMS highlighted by clinical pharmacists in an emergency unit during summer. One of them was fatal. Medication reconciliation processes performed at admission identified treatment with loxapine for one of them and with loxapine and clozapine for the other. Interview of the patients highlighted clinical symptoms suggesting NMS, allowing the pharmacists to alert the medical team. WHAT IS NEW AND
CONCLUSION: Adverse drug events may be severe and clinical pharmacists in emergency departments can help to detect them.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  accident and emergency departments; adverse effect; clinical pharmacy; clozapine; loxapine; pharmacist consultation

Mesh:

Substances:

Year:  2017        PMID: 28488314     DOI: 10.1111/jcpt.12531

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  3 in total

1.  Impact of pharmacists on outcomes for patients with psychiatric or neurologic disorders.

Authors:  Amy Werremeyer; Jolene Bostwick; Carla Cobb; Tera D Moore; Susie H Park; Cristofer Price; Jerry McKee
Journal:  Ment Health Clin       Date:  2020-11-05

2.  Psychiatric pharmacist's role in overcoming barriers to clozapine use and improving management.

Authors:  Deanna L Kelly; Raymond C Love
Journal:  Ment Health Clin       Date:  2019-03-01

3.  Impact of a medico-pharmaceutical follow-up and an optimized communication between hospital and community on the readmission to the emergency department for an adverse drug event: URGEIM, study protocol for a randomized controlled trial.

Authors:  Cyril Breuker; Marie Faucanié; Marion Laureau; Damien Perier; Véronique Pinzani; Grégory Marin; Mustapha Sebbane; M Villiet
Journal:  Trials       Date:  2021-08-06       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.